0001636050-21-000046.txt : 20210419
0001636050-21-000046.hdr.sgml : 20210419
20210419165349
ACCESSION NUMBER: 0001636050-21-000046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210415
FILED AS OF DATE: 20210419
DATE AS OF CHANGE: 20210419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nassif David W.
CENTRAL INDEX KEY: 0001636975
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 21835197
MAIL ADDRESS:
STREET 1: C/O STEADYMED THERAPEUTICS, INC.
STREET 2: 2410 CAMINO RAMON
CITY: SAN RAMON
STATE: CA
ZIP: 94583
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sio Gene Therapies Inc.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 853863315
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 130 WEST 42ND STREET
STREET 2: 26TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 877-746-4891
MAIL ADDRESS:
STREET 1: 130 WEST 42ND STREET
STREET 2: 26TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Gene Therapies Ltd.
DATE OF NAME CHANGE: 20190516
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
4
1
wf-form4_161886561553902.xml
FORM 4
X0306
4
2021-04-15
0
0001636050
Sio Gene Therapies Inc.
SIOX
0001636975
Nassif David W.
C/O SIO GENE THERAPIES INC.
130 WEST 42ND STREET, 26TH FLOOR
NEW YORK
NY
10036
0
1
0
0
Chief Financial Officer
Stock Option (Right to Buy)
2.47
2021-04-15
4
A
0
239000
0
A
2031-04-14
Common Stock
239000.0
239000
D
The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.
/s/ David Nassif
2021-04-19